Treatment of Cushing's Disease With R-roscovitine

Cushings Disease Clinical Trial

Official title:

Treatment of Pituitary Cushing Disease With a Selective CDK Inhibitor, R-roscovitine

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT02160730
• Other study ID #: Pro35720
• Secondary ID: 1R21DK103198-01
• Status: Terminated
• Phase: Phase 2
• Start date: May 2014
• Est. completion date: October 2018

Study information

• Verified date: November 2021
• Source: Cedars-Sinai Medical Center
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The investigators hypothesize that R-roscovitine will suppress pituitary corticotroph tumor ACTH production and normalize urinary free cortisol levels in patients with Cushing disease. To date, R-roscovitine has been evaluated in several Phase I and II studies and has shown early signs of anti-cancer activity in approximately 240 patients.

Description:

To date, R-roscovitine (seliciclib) has been evaluated in several Phase I and II studies and has shown early signs of anti-cancer activity in approximately 240 patients. Studies included a Phase I study in which single agent seliciclib was administered to patients with advanced non-small cell lung cancer (NSCLC) and two Phase IIa studies in which seliciclib was administered in combination with gemcitabine and cisplatin as first-line treatment and with docetaxel as second-line treatment in NSCLC. Seliciclib was also evaluated in a Phase I study in patients with nasopharyngeal cancer (NPC) with evidence of tumor shrinkage and concomitant reduction in copy counts of the EBV virus that is causally associated with the pathogenesis of NPC. Results from APPRAISE, a randomized discontinuation, double-blinded, placebo-controlled, Phase IIb study of oral seliciclib capsules as a monotherapy in heavily pretreated patients with NSCLC, demonstrated no difference between the seliciclib and placebo arms in progression free survival but a substantial increase in overall survival was observed (388 versus 218 days respectively (Cyclacel Pharmaceuticals press release Dec 21, 2010). Here, the investigators propose an exploratory, proof of concept clinical trial to determine if seliciclib can safely normalize urinary free cortisol levels by reducing pituitary corticotroph tumor ACTH production in patients with Cushing disease.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 4
• Est. completion date: October 2018
• Est. primary completion date: October 2018
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion criteria:

• Male and female patients at least 18 years old

• Patients with confirmed pituitary origin of excess adrenocorticotropic hormone (ACTH) production:

• Persistent hypercortisolemia established by two consecutive 24 h UFC levels at least 1.5x the upper limit of normal

• Normal or elevated ACTH levels

• Pituitary macroadenoma (>1 cm) on MRI OR

• Inferior Petrosal Sinus Sampling (IPSS) central to peripheral ACTH gradient >2 at baseline and >3 after CRH stimulation

• Recurrent or persistent Cushing disease is defined as pathologically confirmed resected pituitary ACTH-secreting tumor, and 24 hour UFC above the upper limit of normal reference range beyond post-surgical week 6

• Patients on medical treatment for Cushing's disease the following washout periods must be completed before screening assessments are performed:

• Inhibitors of steroidogenesis (metyrapone, ketoconazole): 2 weeks

• Somatostatin analogs (pasireotide): 2 weeks

• Progesterone receptor antagonist (mifepristone): 2 weeks

• Dopamine agonists (cabergoline): 4 weeks

• CYP3A4 strong inducers or inhibitors: varies between drugs; minimum 5-6 times the half-life of drug

Exclusion criteria:

• Patients with compromised visual fields, and not stable for at least 6 months

• Patients with abutment or compression of the optic chiasm on MRI and normal visual fields

• Patients with Cushing's syndrome due to non-pituitary ACTH secretion

• Patients with hypercortisolism secondary to adrenal tumors or nodular (primary) bilateral adrenal hyperplasia

• Patients who have a known inherited syndrome as the cause for hormone over secretion (i.e. Carney Complex, McCune-Albright syndrome, MEN-1)

• Patients with a diagnosis of glucocorticoid-remedial aldosteronism (GRA)

• Patients with cyclic Cushing's syndrome defined by any measurement of UFC over the previous 1 months within normal range

• Patients with pseudo-Cushing's syndrome, i.e. non-autonomous hypercortisolism due to overactivation of the HPA axis in uncontrolled depression, anxiety, obsessive compulsive disorder, morbid obesity, alcoholism, and uncontrolled diabetes mellitus

• Patients who have undergone major surgery within 1 month prior to screening

• Patients with serum K+< 3.5 while on replacement treatment

• Diabetic patients whose blood glucose is poorly controlled as evidenced by HbA1C >8%

• Patients who have clinically significant impairment in cardiovascular function or are at risk thereof, as evidenced by

• Congestive heart failure (NYHA Class III or IV), unstable angina, sustained ventricular tachycardia, clinically significant bradycardia, high grade AV block, history of acute MI less than one year prior to study entry

• Patients with liver disease or history of liver disease such as cirrhosis, chronic active hepatitis B and C, or chronic persistent hepatitis, or patients with ALT or AST more than 1.5 x ULN, serum total bilirubin more than ULN, serum albumin less than 0.67 x LLN at screening

• Serum creatinine > 2 x ULN

• Patients not biochemically euthyroid

• Patients who have any current or prior medical condition that can interfere with the conduct of the study or the evaluation of its results, such as

• History of immunocompromise, including a positive HIV test result (Elisa and Western blot). An HIV test will not be required, however, previous medical history will be reviewed

• Presence of active or suspected acute or chronic uncontrolled infection

• History of, or current alcohol misuse/abuse in the 12 month period prior to screening

• Female patients who are pregnant or lactating, or are of childbearing potential and not practicing a medically acceptable method of birth control. If a woman is participating in the trial then one form of contraception is sufficient (pill or diaphragm) and the partner should use a condom. If oral contraception is used in addition to condoms, the patient must have been practicing this method for at least two months prior to screening and must agree to continue the oral contraceptive throughout the course of the study and for 3 months after the study has ended. Male patients who are sexually active are required to use condoms during the study and for three month afterwards as a precautionary measure (available data do not suggest any increased reproductive risk with the study drugs)

• Patients who have participated in any clinical investigation with an investigational drug within 1 month prior to screening or patients who have previously been treated with seliciclib

• Patients with any ongoing or likely to require additional concomitant medical treatment to seliciclib for the tumor

• Patients with concomitant treatment of strong CYP3A4 inducers or inhibitors.

• Patients who were receiving mitotane and/or long-acting somatostatin analogs (octreotide LAR or lanreotide)

• Patients who were receiving pasireotide or ketoconazole before study entry must complete a 2 week washout period prior to receiving seliciclib

• Patients who have received pituitary irradiation within the last 5 years prior to the baseline visit

• Patients who have been treated with radionuclide at any time prior to study entry

• Patients with known hypersensitivity to seliciclib

• Patients with a history of non-compliance to medical regimens or who are considered potentially unreliable or will be unable to complete the entire study

• Patients with presence of Hepatitis B surface antigen (HbsAg)

• Patients with presence of Hepatitis C antibody test (anti-HCV)

Related Conditions & MeSH terms

• ACTH-Secreting Pituitary Adenoma
• Cushings Disease
• Pituitary ACTH Hypersecretion

Intervention

Drug:
• R-roscovitine
See Arm Description

Locations

Country	Name	City	State
United States	Cedars-Sinai Medical Center	Los Angeles	California

Sponsors (2)

Lead Sponsor	Collaborator
Shlomo Melmed, MD	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Country where clinical trial is conducted

United States, 

References & Publications (27)

Biller BM, Grossman AB, Stewart PM, Melmed S, Bertagna X, Bertherat J, Buchfelder M, Colao A, Hermus AR, Hofland LJ, Klibanski A, Lacroix A, Lindsay JR, Newell-Price J, Nieman LK, Petersenn S, Sonino N, Stalla GK, Swearingen B, Vance ML, Wass JA, Boscaro M. Treatment of adrenocorticotropin-dependent Cushing's syndrome: a consensus statement. J Clin Endocrinol Metab. 2008 Jul;93(7):2454-62. doi: 10.1210/jc.2007-2734. Epub 2008 Apr 15. Review. — View Citation

Bilodeau S, Vallette-Kasic S, Gauthier Y, Figarella-Branger D, Brue T, Berthelet F, Lacroix A, Batista D, Stratakis C, Hanson J, Meij B, Drouin J. Role of Brg1 and HDAC2 in GR trans-repression of the pituitary POMC gene and misexpression in Cushing disease. Genes Dev. 2006 Oct 15;20(20):2871-86. — View Citation

Chesnokova V, Zonis S, Kovacs K, Ben-Shlomo A, Wawrowsky K, Bannykh S, Melmed S. p21(Cip1) restrains pituitary tumor growth. Proc Natl Acad Sci U S A. 2008 Nov 11;105(45):17498-503. doi: 10.1073/pnas.0804810105. Epub 2008 Nov 3. — View Citation

Chesnokova V, Zonis S, Zhou C, Ben-Shlomo A, Wawrowsky K, Toledano Y, Tong Y, Kovacs K, Scheithauer B, Melmed S. Lineage-specific restraint of pituitary gonadotroph cell adenoma growth. PLoS One. 2011 Mar 25;6(3):e17924. doi: 10.1371/journal.pone.0017924. — View Citation

Fleseriu M, Biller BM, Findling JW, Molitch ME, Schteingart DE, Gross C; SEISMIC Study Investigators. Mifepristone, a glucocorticoid receptor antagonist, produces clinical and metabolic benefits in patients with Cushing's syndrome. J Clin Endocrinol Metab. 2012 Jun;97(6):2039-49. doi: 10.1210/jc.2011-3350. Epub 2012 Mar 30. — View Citation

Geng Y, Eaton EN, Picón M, Roberts JM, Lundberg AS, Gifford A, Sardet C, Weinberg RA. Regulation of cyclin E transcription by E2Fs and retinoblastoma protein. Oncogene. 1996 Mar 21;12(6):1173-80. — View Citation

Henry RR, Ciaraldi TP, Armstrong D, Burke P, Ligueros-Saylan M, Mudaliar S. Hyperglycemia associated with pasireotide: results from a mechanistic study in healthy volunteers. J Clin Endocrinol Metab. 2013 Aug;98(8):3446-53. doi: 10.1210/jc.2013-1771. Epub 2013 Jun 3. — View Citation

Jordan S, Lidhar K, Korbonits M, Lowe DG, Grossman AB. Cyclin D and cyclin E expression in normal and adenomatous pituitary. Eur J Endocrinol. 2000 Jul;143(1):R1-6. — View Citation

Kossatz U, Breuhahn K, Wolf B, Hardtke-Wolenski M, Wilkens L, Steinemann D, Singer S, Brass F, Kubicka S, Schlegelberger B, Schirmacher P, Manns MP, Singer JD, Malek NP. The cyclin E regulator cullin 3 prevents mouse hepatic progenitor cells from becoming tumor-initiating cells. J Clin Invest. 2010 Nov;120(11):3820-33. doi: 10.1172/JCI41959. Epub 2010 Oct 11. — View Citation

Lamolet B, Pulichino AM, Lamonerie T, Gauthier Y, Brue T, Enjalbert A, Drouin J. A pituitary cell-restricted T box factor, Tpit, activates POMC transcription in cooperation with Pitx homeoproteins. Cell. 2001 Mar 23;104(6):849-59. — View Citation

Lapenna S, Giordano A. Cell cycle kinases as therapeutic targets for cancer. Nat Rev Drug Discov. 2009 Jul;8(7):547-66. doi: 10.1038/nrd2907. Review. — View Citation

Legraverend M, Grierson DS. The purines: potent and versatile small molecule inhibitors and modulators of key biological targets. Bioorg Med Chem. 2006 Jun 15;14(12):3987-4006. Epub 2006 Feb 24. Review. — View Citation

Liu NA, Jiang H, Ben-Shlomo A, Wawrowsky K, Fan XM, Lin S, Melmed S. Targeting zebrafish and murine pituitary corticotroph tumors with a cyclin-dependent kinase (CDK) inhibitor. Proc Natl Acad Sci U S A. 2011 May 17;108(20):8414-9. doi: 10.1073/pnas.1018091108. Epub 2011 May 2. — View Citation

Loeb KR, Kostner H, Firpo E, Norwood T, D Tsuchiya K, Clurman BE, Roberts JM. A mouse model for cyclin E-dependent genetic instability and tumorigenesis. Cancer Cell. 2005 Jul;8(1):35-47. — View Citation

Ma Y, Fiering S, Black C, Liu X, Yuan Z, Memoli VA, Robbins DJ, Bentley HA, Tsongalis GJ, Demidenko E, Freemantle SJ, Dmitrovsky E. Transgenic cyclin E triggers dysplasia and multiple pulmonary adenocarcinomas. Proc Natl Acad Sci U S A. 2007 Mar 6;104(10):4089-94. Epub 2007 Feb 27. — View Citation

Melmed S. Pathogenesis of pituitary tumors. Nature reviews Endocrinology. 2011;7(5):257-66. Epub 2011/03/23. doi: 10.1038/nrendo.2011.40. PubMed PMID: 21423242.

Minella AC, Loeb KR, Knecht A, Welcker M, Varnum-Finney BJ, Bernstein ID, Roberts JM, Clurman BE. Cyclin E phosphorylation regulates cell proliferation in hematopoietic and epithelial lineages in vivo. Genes Dev. 2008 Jun 15;22(12):1677-89. doi: 10.1101/gad.1650208. — View Citation

Nieman LK, Biller BM, Findling JW, Newell-Price J, Savage MO, Stewart PM, Montori VM. The diagnosis of Cushing's syndrome: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2008 May;93(5):1526-40. doi: 10.1210/jc.2008-0125. Epub 2008 Mar 11. — View Citation

Pei L, Melmed S. Isolation and characterization of a pituitary tumor-transforming gene (PTTG). Mol Endocrinol. 1997 Apr;11(4):433-41. — View Citation

Quereda V, Malumbres M. Cell cycle control of pituitary development and disease. J Mol Endocrinol. 2009 Feb;42(2):75-86. doi: 10.1677/JME-08-0146. Epub 2008 Nov 5. Review. — View Citation

Roussel-Gervais A, Bilodeau S, Vallette S, Berthelet F, Lacroix A, Figarella-Branger D, Brue T, Drouin J. Cooperation between cyclin E and p27(Kip1) in pituitary tumorigenesis. Mol Endocrinol. 2010 Sep;24(9):1835-45. doi: 10.1210/me.2010-0091. Epub 2010 Jul 21. — View Citation

Sengupta T, Abraham G, Xu Y, Clurman BE, Minella AC. Hypoxia-inducible factor 1 is activated by dysregulated cyclin E during mammary epithelial morphogenesis. Mol Cell Biol. 2011 Sep;31(18):3885-95. doi: 10.1128/MCB.05089-11. Epub 2011 Jul 11. — View Citation

Siegel-Lakhai Wea. ASCO Proceedings, Abs 2060. 2005.

Vlotides G, Eigler T, Melmed S. Pituitary tumor-transforming gene: physiology and implications for tumorigenesis. Endocr Rev. 2007 Apr;28(2):165-86. Epub 2007 Feb 26. Review. — View Citation

Wesierska-Gadek J, Krystof V. Selective cyclin-dependent kinase inhibitors discriminating between cell cycle and transcriptional kinases: future reality or utopia? Ann N Y Acad Sci. 2009 Aug;1171:228-41. doi: 10.1111/j.1749-6632.2009.04726.x. Review. — View Citation

Yeo et al. J Clin Oncol 2009 27-15s (Suppl abstr 6026).

Zhang HS, Gavin M, Dahiya A, Postigo AA, Ma D, Luo RX, Harbour JW, Dean DC. Exit from G1 and S phase of the cell cycle is regulated by repressor complexes containing HDAC-Rb-hSWI/SNF and Rb-hSWI/SNF. Cell. 2000 Mar 31;101(1):79-89. — View Citation

* Note: There are 27 references in all — Click here to view all references

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of Participants With a Normalized 24 Hour Urinary Free Cortisol After 4 Weeks	To evaluate the efficacy of R-roscovitine 400 mg oral administration twice daily for 4 days every week for total of 4 weeks on normalizing 24 hour urinary free cortisol (24 h UFC) levels in CD patients. "Normalizing" is defined as having urine free cortisol levels within the normal range for that lab value.	Baseline, 4 weeks
Secondary	Change in Mean HbA1c Levels Between Baseline and 4 Weeks	HbA1c levels are measured at baseline and at study end, these are averaged across all subjects.	Baseline, 4 Weeks
Secondary	Number of Participants With Adverse Events	The number of participants that experience an adverse event between baseline and study end likely related to study drug as a measure of safety and tolerability.	Baseline, 4 weeks
Secondary	Number of Participants That Have a Visible Change in Tumor Size	A visible change in tumor size as determined by the investigator after reviewing MRI reports between baseline and 4 weeks of treatment.	Baseline, 4 weeks
Secondary	Number of Participants That Experience Changes in Clinical Signs of Hypercortisolemia	The number of participants that achieved a urinary free cortisol level above the upper limit of the normal range but reduced by =50% from baseline at week 4.	Baseline, Week 4
Secondary	Fasting Glucose at Baseline and 4 Weeks	Mean change between baseline and week 4 of fasting blood glucose levels.	Baseline, 4 Weeks
Secondary	Plasma ACTH at Baseline and 4 Weeks	Mean change in Plasma ACTH between baseline and 4 weeks.	Baseline, 4 weeks
Secondary	Change in Clinical Symptoms	Change in typical Cushing's syndrome clinical signs and symptoms defined by mean weight at baseline and 4 weeks.	Baseline, 4 weeks
Secondary	Changes in Serum Cortisol Between Baseline and 4 Weeks	Mean serum cortisol values at baseline and 4 weeks	Baseline, 4 weeks
Secondary	Change in Systolic Blood Pressure	Mean change in systolic blood pressure between baseline and 4 weeks.	Baseline, 4 weeks
Secondary	Change in Diastolic Blood Pressure	Mean diastolic blood pressure between baseline and 4 weeks.	Baseline, 4 weeks